irinotecan has been researched along with Carcinoma, Bronchogenic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harr, MW; Willey, JC | 1 |
1 other study(ies) available for irinotecan and Carcinoma, Bronchogenic
| Article | Year |
|---|---|
The interactive transcript abundance index [c-myc*p73alpha]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; In Situ Nick-End Labeling; Irinotecan; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA Precursors | 2007 |